Company and Stock Identity

How Avicenna.AI Connects to the Public Market

Company structure
Private company
Market access
No current public listing was verified.
Research focus
Each CINA product carries its own clearance, granted in a different year, so match the product you are buying to the clearance that covers that finding on that scan type rather than reading the clearance list as one approval. The company publishes a clinical publications page, which is the place to start on measured performance.

Avicenna.AI was founded in 2018 and incorporated in La Ciotat, France, by Cyril Di Grandi and Peter Chang, MD, who are listed as chief executive and chief medical officer. The company's own pages do not name investors or state funding amounts. No ownership change was found as of October 10, 2026.

Open the public company market data feed for the full directory, ownership relationships, stock identifiers, and dated snapshots.

First-Hand Company News

Latest Developments

... Avicenna.AI ... Company research

Avicenna.AI gathers six published studies on its clot detection tool in one place

Avicenna.AI published on June 3, 2026 a review of six peer-reviewed studies covering AI detection of pulmonary embolism on CT pulmonary angiography. The company reports that in a real-world study of 1,204 examinations, clot-positive cases not reported at first read fell from 15.6 percent to 3.8 percent, with per-case sensitivity of 93.9 percent and specificity of 94.8 percent. It reports time from scan to specialist consult falling from 241 minutes to 6.7 minutes at one US referral centre, scan-to-alert time falling from 318 minutes to 5.47 minutes in a follow-up at the same institution, and in-hospital deaths falling from 8.4 percent among 113 patients before deployment to 2.2 percent among 45 patients after. In a reader study of 207 examinations, radiology residents reached 92.5 percent sensitivity with the tool against 81.7 percent without it. Avicenna.AI describes the product, CINA-PE, as a CE marked Class IIb decision-support tool with FDA 510(k) clearance K210237. This site's own FDA device records list K210237 as a 510(k) clearance decided on May 19, 2021 under the applicant name Avicenna.Ai, recorded there with the device name CINA CHEST.

Why it matters: Publishing six studies with confidence intervals, rather than one percentage on a slide, is the behaviour a cautious buyer should reward, and the sensitivity figures hold up across several CT vendors and scanner models. The weakest numbers in the set are the mortality ones, because 113 patients before and 45 after is a small single-site comparison where staffing, triage habits and case mix all changed at the same time as the software. The time-to-consult drop from four hours to minutes is the result most likely to repeat elsewhere, since a faster alert does not depend on the model being clever, only on it firing.

... Avicenna.AI ... Company source

Avicenna.AI and Bracco Imaging are building brain CT angiography AI, with an FDA filing planned

Avicenna.AI said on 2 March 2026 that it entered a strategic partnership with Bracco Imaging on computer-aided detection and diagnosis in brain CT angiography. The companies say the work is progressing through development and clinical validation at selected sites in the United States and Europe, with Avicenna.AI contributing image interpretation AI and Bracco Imaging extending its contrast-enhanced CT capability. The announcement states that an FDA submission for the new AI applications is foreseen in the second half of 2026, and names no product.

Why it matters: The honest status here is pre-submission, which is the distinction a buyer should hold onto: a planned FDA filing in the second half of 2026 is not a clearance, and a clearance is not a given. The pairing itself is the interesting part, because a contrast agent company has a commercial reason to make the scan easier to read and already sells into the departments Avicenna.AI wants. For Avicenna.AI, whose seven existing clearances are all for triage and lesion software, moving into detection and diagnosis on contrast-enhanced CT is a step up in regulatory difficulty, not a product extension.

... Avicenna.AI ... Company source

Avicenna.AI launches AVI, a platform that delivers its CINA results without a new viewer

Avicenna.AI said on 13 November 2025 that it launched AVI, a platform that delivers AI results into existing hospital systems. The company says it integrates directly with PACS and RIS without an extra viewer or a change to the workflow, runs fully automatically and is invisible to end users, and simplifies deployment for IT teams. It says the platform initially hosts the CINA portfolio, naming CINA-ICH, CINA-LVO and CINA-ASPECTS for neuro, CINA-VCF, CINA-VCF Quantix and CINA-CSpine for spine, and CINA-AD, CINA-PE and CINA-iPE for chest. Avicenna.AI says AVI supports workflows compliant with GDPR and HIPAA, de-identifying data before processing and re-identifying it on return, with encryption and access controls.

Why it matters: The delivery layer is usually what kills imaging AI projects, not the algorithm, so a vendor shipping its own integration path instead of asking for another workstation is addressing the real obstacle. Listing all nine CINA products on one platform also means a department can add findings without another integration project, which is how this kind of purchase actually grows. Note what the platform is not: AVI is plumbing, and each CINA product carries its own clearance, so the platform does not extend any product's permitted use. The de-identification step is worth checking in detail, since it is the company's description of its own design rather than an audited control.

See company developments across the healthcare AI market.

Careers and Qualifications

What to Know Before Applying

Work areas: Deployment and technical support sits under customer success, alongside the AI research, regulatory and engineering work behind a cleared imaging product. The team shown on the company page is small, around two dozen people.

Qualification signal: Experience taking a regulated imaging product through clearance and into a hospital imaging workflow counts for more here than general AI coursework. The open role the company lists is onsite in La Ciotat, France, so location matters.

Check current roles at Avicenna.AI. A careers page is the source of record for openings. This profile does not claim a role is open unless the company lists it now.

Related Healthcare AI Roles

Training to Compare

Buyer Snapshot

Best-fit buyer
Radiology leadership, pathology leadership, clinical informatics, imaging IT, patient safety, and procurement
Primary use case
Triage studies, flag findings, support image interpretation, and coordinate time-sensitive care
Typical deployment
Usually integrated with PACS, RIS, worklists, or digital pathology systems and monitored inside the clinical workflow

Evidence questions

  • Was the tool tested prospectively and independently on comparable equipment and patients?
  • What are sensitivity, specificity, false positive workload, and time-to-action effects?
  • How does performance vary by site, scanner, demographic subgroup, and disease prevalence?

Regulatory and workflow questions

  • Which FDA authorization covers the exact product version, modality, and intended use?
  • Who retains final clinical responsibility and how is disagreement with the AI handled?
  • What post-deployment monitoring and material update notification does the vendor provide?

Data and contract questions

  • Where are images and derived data processed and retained?
  • Which PACS, RIS, pathology, and EHR integrations are supported in production?
  • Can data be used for model improvement, and what controls govern secondary use?

Evidence and Regulation

FDA Clearances on Record

Avicenna.AI appears on 7 cleared products in the federal 510(k) record, across 3 device types.

A clearance means the FDA agreed the product is close enough to something already on the market to be sold for that use. It is not a finding that the product helps patients, and it is not a ranking against anything else on this page. A company is linked to an FDA clearance only when the 510(k) applicant name on the government record is confirmed by hand to be that same company, including former corporate names. Name similarity alone is never enough, and rejected matches are listed below with the reason.

What the Published Research Says About This Work

Independent studies on the work itself help separate category evidence from one company's claims.

First-Hand Sources